Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.11861/7390
Title: Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma
Authors: Xia, Zhong-Kun 
Wang, Wei 
Qiu, Jian-Ge 
Shi, Xi-Nan 
Li, Hong-Jian 
Chen, Rong 
Ke, Kun-Bin 
Dong, Chao 
Zhu, Ying 
Wu, Shi-guo 
Zhang, Rong-Ping 
Meng, Zhuo-Ran 
Zhao. Hui 
Gu, Peng 
Prof. LEUNG Kwong Sak 
Wong, Man-Hon 
Liu, Xiao-Dong 
Zhou, Feng- Mei 
Zhang, Jian-ying 
Yao, Ya-Ting 
Wang, Si-Jia 
Zhang, Chun-Yang 
Qin, Yan-Ru 
Lin, Marie, Chia-mi 
Jiang, Bing-Hua 
Issue Date: 2021
Source: Frontiers in Pharmacology, 2021, vol. 12
Journal: Frontiers in Pharmacology 
Abstract: Background: Hepatocellular carcinoma (HCC) is a lethal malignancy lacking effective treatment. The Cyclin-dependent kinases 4/6 (CDK4/6) and PI3K/AKT signal pathways play pivotal roles in carcinogenesis and are promising therapeutic targets for HCC. Here we identified a new CDK4/6 and PI3K/AKT multi-kinase inhibitor for the treatment of HCC. Methods: Using a repurposing and ensemble docking methodology, we screened a library of worldwide approved drugs to identify candidate CDK4/6 inhibitors. By MTT, apoptosis, and flow cytometry analysis, we investigated the effects of candidate drug in reducing cell-viability,inducing apoptosis, and causing cell-cycle arrest. The drug combination and thermal proteomic profiling (TPP) method were used to investigate whether the candidate drug produced antagonistic effect. The in vivo anti-cancer effect was performed in BALB/C nude mice subcutaneously xenografted with Huh7 cells. Results: We demonstrated for the first time that the anti-plasmodium drug aminoquinol is a new CDK4/6 and PI3K/AKT inhibitor. Aminoquinol significantly decreased cell viability, induced apoptosis, increased the percentage of cells in G1 phase. Drug combination screening indicated that aminoquinol could produce antagonistic effect with the PI3K inhibitor LY294002. TPP analysis confirmed that aminoquinol significantly stabilized CDK4, CDK6, PI3K and AKT proteins. Finally, in vivo study in Huh7 cells xenografted nude mice demonstrated that aminoquinol exhibited strong anti-tumor activity, comparable to that of the leading cancer drug 5-fluorouracil with the combination treatment showed the highest therapeutic effect. Conclusion: The present study indicates for the first time the discovery of a new CDK4/6 and PI3K/AKT multi-kinase inhibitor aminoquinol. It could be used alone or as a combination therapeutic strategy for the treatment of HCC.
Type: Peer Reviewed Journal Article
URI: http://hdl.handle.net/20.500.11861/7390
ISSN: 1663-9812
DOI: 10.3389/fphar.2021.691769
Appears in Collections:Applied Data Science - Publication

Show full item record

SCOPUSTM   
Citations

5
checked on Dec 15, 2024

Page view(s)

42
Last Week
0
Last month
checked on Dec 20, 2024

Google ScholarTM

Impact Indices

Altmetric

PlumX

Metrics


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.